On May 2017, a case of dengue serotype 1 was detected and confirmed through routine surveillance in a traveler returning from Kribi, a seaside town of Southern Cameroon. This study aimed at confirming the circulation of dengue virus (DENV) in Southern Cameroon. A cross sectional study was carried out in Londji near Kribi from June 21-25, 2017, by a joint team of Centre Pasteur of Cameroon and the Department of Diseases, Epidemics and Pandemics Control. Blood samples of consented participants were collected and tested for anti-D ENV IgM using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA), and for the detection of Zika, dengue, or chikungunya viruses using Trioplex real-time reverse transcription-polymerase chain reaction (RT-PCR). DENV RNA-positive samples were serotyped using an end-point nested RT-PCR. Ninety-one participants were enrolled, 50.55% (46/91) of them males. The mean age of the population was 30.71 years (±18.89). In total, 14.28% (13/91) of the participants had DENV infection (3 anti-DENV IgM positive and 10 DENV serotype 1 RT-PCR positive). The detection of DENV serotype 1 in an autochthonous population during this survey is a confirmation that the seaside city of Kribi is a risk area for contracting dengue infection in Cameroon.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.